Abstract
Germline mutations of CHEK2 have been reported in various types of disease including breast cancer, ovarian cancer, colorectal cancer and prostate cancer. We generated two iPSC lines ZNHi001-A and ZNHi001-B from a prostate cancer patient carrying germline mutation in CHEK2 (c.667C＞T, also p.R223C) which may increase the risk of prostate cancer. Pluripotency and multi-lineage differentiation capacity of the two iPSC lines were confirmed by gene expression and teratoma assay. The generated iPSC lines carrying specific CHEK2 mutation might be a useful resource to study the pathogenic mechanism and develop potential therapeutic strategy of prostate cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
